FDA Warning Letter Asks Bayer To Fix Manufacturing Practices In German Facility
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says Bayer's facility in Bergkamen, Germany, is still not up to par with good manufacturing practices in the U.S.
You may also be interested in...
Bayer Management Changes May Suggest Deepening Xarelto Concerns
Delayed appointments of new CEO and CFO may strengthen German pharma's M&A capabilities.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: